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ABSTRACT
Introduction Statins, also known as 3- hydroxy-3- 
methylglutaryl coenzyme- A (HMG- CoA) reductase inhibitors, 
are lipid- lowering agents that are central in preventing or 
reducing the complications of atherosclerotic cardiovascular 
disease. Because statins have anti- inflammatory properties, 
there is considerable interest in their therapeutic potential 
in other chronic inflammatory conditions. We aim to identify 
the statin with the greatest ability to reduce systemic 
inflammation, independent of the underlying disease entity.
Methods and analysis We aim to conduct a comprehensive 
search of published and peer- reviewed randomised 
controlled clinical trials, with at least one intervention arm 
of a Food & Drug Administration- licensed or European 
Medicines Agency- licensed statin and a minimum treatment 
duration of 12 weeks. Our objective is to investigate the 
effect of statins (atorvastatin, fluvastatin, pitavastatin, 
pravastatin, rosuvastatin, simvastatin) on lipid profile, 
particularly, cholesterol low- density lipoprotein and 
inflammation markers such as high- sensitive C reactive 
protein (hsCRP), CRP, tumour necrosis factor alpha 
(TNF-α), interleukin-1β (IL-1β), IL-6, IL-8, soluble cluster 
of differentiation 14 (sCD14) or sCD16 in adults, published 
in the last 20 years (between January 1999 and December 
2019). We aim to identify the most potent statin to reduce 
systemic inflammation and optimal dosing. The following 
databases will be searched: Medline, Scopus, Web of Science 
and Cochrane Library of Systematic Reviews. The risk of bias 
of included studies will be assessed by Cochrane Risk of Bias 
Tool and Quality Assessment Tool for Quantitative Studies. 
The quality of studies will be assessed, to show uncertainty, 
by the Jadad Score. If sufficient evidence is identified, a 
meta- analysis will be conducted with risk ratios or ORs with 
95% CIs in addition to mean differences.
Ethics and dissemination Ethics approval is not 
required as no primary data will be collected. Results will 
be presented at conferences and published in a peer- 
reviewed journal.
PROSPERO registration number CRD42020169919
INTRODUCTION
Statins are US Food & Drug Administra-
tion (FDA) approved lipid- lowering drugs 
(table 1) that have been on the market for 
more than 30 years1 and are widely prescribed 
to patients who are at high risk of cardiovas-
cular diseases.2 Statins exert their function 
via inhibiting 3- hydroxy-3- methylglutaryl 
coenzyme- A (HMG- CoA) reductase which 
converts HMG- CoA into L- mevalonate 
resulting in reduced cholesterol biosyn-
thesis.3 The cholesterol biosynthesis inhibi-
tion via statins results in the upregulation of 
low- density lipoprotein (LDL) receptors on 
the cell surface which consequently leads to 
increased uptake and clearance of LDL in 
the circulating blood. This ultimately lowers 
LDL- cholesterol (LDL- C) and decreases the 
risk associated with lipoprotein deposition in 
the arterial wall and progression to athero-
sclerosis and vascular disease. In addition to 
statins’ LDL- C lowering ability, statins also 
inhibit protein prenylation,4 which is an 
important biological process that mediates 
protein- protein interaction and anchoring of 
cell membrane proteins.5 The ability of statins 
to inhibit isoprenoids, important metabolites 
in the protein prenylation pathway, accounts 
Strengths and limitations of this study
 ► This study will include randomised controlled clinical 
trials to determine the most effective statin on the 
combined reduction of lipid profile and inflammatory 
biomarkers.
 ► High- quality clinical trials will be reviewed accurate-
ly to generate reliable evidence.
 ► This study will be conducted following Preferred 
Reporting Items for Systematic Review and Meta- 
Analysis Protocol guidelines.
 ► Variation of statin doses among included studies will 
likely produce heterogeneity that will subsequently 
reduce the sample size of the meta- analysis.
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for their lipid- independent pleiotropic effects.6 7 Indeed 
statins have been reported to have anti- inflammatory, 
antioxidant antiproliferative and immunomodulatory 
effects independent of their cholesterol- lowering ability.8 
The reported vascular effects of statins are wide- ranging 
and include improvement of endothelial functioning, 
decreasing oxidative stress and maintenance of coronary 
artery plaque stability.8 Statins may also lower the risk of 
liver cancer.9 The anti- inflammatory effects vary among 
the different types of currently licensed statins with 
various meta- analyses reporting differential efficacy in 
reducing inflammation in chronic obstructive pulmonary 
disease (COPD).10 Statins (table 1) are categorised into 
two main groups according to their solubility: (1) hydro-
philic statins which include pravastatin and rosuvastatin 
and these display high hepato- selectivity with increased 
first- pass effect and (2) lipophilic statins which are char-
acterised by passive diffusion into cells; these include 
atorvastatin, simvastatin, lovastatin, fluvastatin, pitavas-
tatin and cerivastatin.11
Statins and inflammation
Inflammatory responses to various clinical conditions 
result in elevated secretion and activity of acute inflam-
matory proteins such as Creactive protein (CRP). In the 
liver, CRP is mainly secreted by hepatocytes in response 
to interleukin-6 (IL-6).12 Increased secretion of IL-6 
and CRP further exacerbate the inflammatory milieu 
through secretion of pro- inflammatory cytokines such as 
tumour necrosis factor (TNF), activation of the comple-
ment pathway, apoptosis, phagocytosis and nitric oxide 
release.13 Previous clinical trials have reported statin 
therapy to reduce CRP levels through an LDL- C indepen-
dent mechanism,14 15 resulting in better clinical outcomes 
in patients with reduced CRP.16 In addition, atorvastatin 
therapy was shown to reduce inflammatory biomarkers 
such as high- sensitive CRP (hsCRP) and IL-6 in patients 
with unstable angina who received the percutaneous 
coronary intervention and furthermore reduced cardiac 
troponin I and creatine kinase muscle brain suggesting 
a reduction in cardiac myocyte necrosis.17 Additionally, 
the PRINCE randomised controlled trial (RCT) reported 
pravastatin (40 mg/day) therapy to have a significant 
reduction in CRP levels following 12 and 24 weeks of treat-
ment.14 Statin therapy further resulted in the downregu-
lation of other inflammatory biomarkers, such as IL-8 and 
sCD14, in patients with coronary artery inflammation.18 19 
Currently it is not fully elicited on how different types of 
statins (hydrophilic or lipophilic, table 1) or the treat-
ment duration differentially affect immune responses.
Mechanisms to reduce inflammation
Statins are selectively taken up by hepatocytes and decrease 
inflammatory responses by regulating the expression of 
various cell surface molecules/receptors, transcription 
factors, cytokines, chemokines and other soluble inflam-
matory mediators.20 Furthermore, their ability to be taken 
up by other cell types, including immune cells, depending S
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on the expression of cell membrane transport proteins 
and their chemical properties.11 21 Statins can enter their 
target cells either through passive diffusion11 or active 
transport which involves transmembrane proteins within 
the organic anionic- transporting polypeptide 21 22 and 
Na+taurocholate cotransporting polypeptides groups.23
Effects on cell surface receptor
Even though statins were shown to have no effect on 
peripheral frequencies of circulating CD14++CD16−, 
CD14++CD16+ and CD14+CD16++ monocyte subsets, statins 
were shown to reduce expression of cell surface recep-
tors such as vascular endothelial growth factor receptor-2, 
toll- like receptor (TLR)-4 and tyrosine kinase receptor 
Tie2 which are involved in proliferation, migration and 
pathogen recognition within all monocyte populations.24 
Furthermore, statins downregulate the expression of 
TLR-2, human leukocyte antigen- DR and CC- chemokine 
receptor-2 on monocytes, while increasing peroxisome 
proliferator activated receptor-γ activity, which enhances 
their anti- inflammatory properties.17 25 The ability of 
statins to reduce chemokine and chemokine receptor 
expression on human vascular endothelial cells and 
human primary macrophages is achieved via inhibition of 
the isoprenoid geranylgeranyl pyrophosphate pathway.26
Effect on cell signalling
Statins are documented to affect cellular functionality of 
both monocytes and T cells through altering activation 
of lymphocyte function- associated antigen (LFA)-1 inte-
grin molecules that are involved in lymphocyte adhesion, 
migration and transduction of co- stimulatory signals to T 
cells during antigen presentation.27 Activation of LFA-1 
integrin molecules leads to conformational changes in 
their structures, thus increasing their binding affinity 
for their respective substrates, which further enhances 
pro- inflammatory responses.28 However, cellular uptake 
of statins is reported to inhibit these conformational 
changes in LFA-1 molecules and further enhance their 
anti- inflammatory properties.27 Statins also modulate 
immune responses through alteration of cell- to- cell inter-
action. Here statins suppress monocyte- derived dendritic 
cells resulting in reduced T cell activation, proliferation 
and T helper differentiation.25
Downstream effects on soluble biomarkers
Statins inhibit monocyte chemoattractant protein-1 secre-
tion, resulting in decreased leucocyte recruitment during 
inflammation.29 Statins suppress the production of pro- 
inflammatory cytokines such as IL-6 and IL-8 in IL-1β-stim-
ulated synoviocytes from rheumatoid arthritis patients via 
interference in protein prenylation and nuclear factor κB 
(NF-κB) pathway.30
Classification of statins
Statins are classified based on several different factors.
Source of origin: They are classified as natural, semi-
synthetic or fully synthetic (table 1). Natural statins are 
acquired from fungal fermentation and these include 
lovastatin. Simvastatin and pravastatin are classified as 
semisynthetic statins because they are produced through 
direct alkylation of lovastatin and hydroxylation of mevas-
tatin, respectively. Fully synthetic statins are produced 
from different substrates and these include pitavastatin, 
rosuvastatin, fluvastatin, atorvastatin and cerivastatin.11
Pharmacological properties: Two pharmacological 
properties differentiate statins; they are either prodrugs 
or active drugs (table 1). Prodrug statins include lovas-
tatin and simvastatin; they are administered in an inac-
tive state and are activated through hydrolysis by liver 
enzymes. Atorvastatin, cerivastatin, fluvastatin and pravas-
tatin are administered as active drugs.11
Physiochemical properties: Statins are classified as lipo-
philic or hydrophilic (table 1). Atorvastatin, simvastatin, 
lovastatin, fluvastatin, cerivastatin and pitavastatin are 
relatively lipophilic statins as they dissolve efficiently in 
lipid/fat solution. Cytochrome P450 enzymes metabolise 
most lipophilic statins except pitavastatin, which is only 
partially metabolised by this pathway. Hydrophilic statins 
such as rosuvastatin and pravastatin are not significantly 
metabolised by the cytochrome P450 system.11 Pravastatin 
and rosuvastatin are classified as hydrophilic statins as 
they dissolve efficiently in water. Pravastatin and rosuvas-
tatin are excreted largely as the parent compound into 
faeces, urine and bile.31 32
Liver selectivity: The hepato- selective processing of 
statins is defined by their solubility profile; therefore, 
lipophilic statins diffused passively through hepatocyte 
cell membranes, whereas hydrophilic statins’ uptake 
occurs through carrier transmembrane proteins.11
Statins in clinical conditions other than cardiovascular 
disease
Inflammation
Statin therapy has been reported to have a wide range of 
potentially beneficial effects. These include the improved 
clinical outcome of chronic kidney disease in patients 
presenting with acute coronary syndrome.33 Statins also 
reduced mortality in patients with cirrhosis with bacter-
aemia and pneumonia.34 Additionally, a 2- year treatment 
period with atorvastatin was associated with milder disease 
progression in patients with relapsing- remitting multiple 
sclerosis.35 However, a study by Birnbaum et al reported 
that disease progression was exacerbated by atorvastatin 
combined with beta interferon in patients with multiple 
sclerosis.36 Moreover, statin users developed significantly 
less uveitis.37 Atorvastatin and rosuvastatin also inhibited 
the micro- inflammatory state and improved the nutri-
tional status in patients who had maintenance haemodi-
alysis.38 In a retrospective observational study, pitavastatin 
usage significantly decreased the mortality risk in Japa-
nese patients who had haemodialysis.39 However, Palmer 
et al published a systemic review of RCTs and reported 
statins to be associated with uncertain adverse events in 
adults treated with dialysis regardless of serum cholesterol 
levels; furthermore, statin treatment showed no beneficial 
effects on mortality and cardiovascular events for patients 
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who had dialysis.40 Rosuvastatin therapy was shown to 
reduce the levels of inflammatory markers, such as IL-6 
and hsCRP, leading to resolved systemic inflammation 
and improved endothelial- dependent vascular function 
in patients with COPD.41 Furthermore, a 6- month atorvas-
tatin (80 mg) therapy improved cough on a quality- of- life 
scale in patients with bronchiectasis.42
Cancer
The Reduction by Dutasteride of Prostate Cancer Events 
(REDUCE) RCT reported the effect of statins; specifically 
simvastatin, lovastatin, atorvastatin and fluvastatin in the 
reduction of inflammatory responses in both acute and 
chronic prostate inflammation.43 Furthermore, in a retro-
spective cohort study, patients with COPD had a lower 
risk of prostate cancer following simvastatin, atorvastatin, 
pravastatin, fluvastatin and lovastatin therapy.44 Inversely, 
an observational study by Emilsson et al that used observa-
tional data from the Surveillance, Epidemiology and End 
Results (SEER)- Medicare Databases on 17 372 patients 
with cancer, reported that treatment with statins within 
6 months after cancer diagnosis did not improve patients’ 
survival rates when followed up for 3 years.45
Central nervous system
Statins have a major effect on the central nervous system, 
particularly on cognition and neurological disorders and 
may decrease the risk of Alzheimer’s disease (AD) and 
Parkinson’s disease through direct impact on neurode-
generation and microglia, respectively.46 However, the 
Lipitor’s effect in Alzheimer’s dementia (LEADc) RCT 
showed that even though atorvastatin (80 mg/day) treat-
ment was well tolerated without unexpected adverse events 
in patients with AD, this treatment did not have signif-
icant beneficial effects on AD over a 72- week period.47 
Additionally, Sano et al further showed in an RCT that 
despite a significant reduction in cholesterol, simvastatin 
(20 mg/day) treatment did not prevent the progression 
of symptoms in individuals with mild to moderate AD.48
Infection
Statins are reported to have a great effect on vaginal 
microbiome via reduced proportions of Gardnerella vagi-
nalis and increased proportions of beneficial lactobacilli.49 
In addition, statins diminished the risk of infections in 
patients with type 2 diabetes.50 Inversely, in patients with 
dementia statin, therapy was associated with increased 
risk of infection.51 However, it was reported that statin 
use in patients with asthma chronic pulmonary disease 
overlap syndrome was associated with lower tuberculosis 
(TB) and pneumonia risks after adjustment for multiple 
confounding factors.52 Statin use was also associated with 
a lower risk of active TB.53 54 Statin therapy also reduced 
the mycobacterial growth in human macrophages and 
mice by induction of autophagy and phagosome matu-
ration.55 Furthermore, many studies have stated the 
potential use of statins as host- directed therapy against 
infectious diseases caused by viruses, protozoa, fungi and 
bacteria.56
Most of the data on statins as therapeutic agents orig-
inate from observational studies. This further highlights 
the need to perform RCTs to evaluate statins’ immuno-
modulatory effects independent of their cholesterol- 
lowering ability. This protocol describes the investigation 
of commonly available statins (table 1) atorvastatin, 
fluvastatin, pitavastatin, pravastatin, rosuvastatin and 
simvastatin focusing on their effect to reduce systemic 
inflammation in humans. Here, cerivastatin and lovas-
tatin will be excluded due to decommissioned status 
from the market and the lack of license in Great Britain 
and Switzerland, respectively. This systematic review will 
address the hypothesis that pravastatin and rosuvastatin 
are inferior to other statins in reducing systemic inflam-
mation due to increased first- pass effect.
OBJECTIVES
Primary objective
To identify the type of statin with the best potential to 
reduce systemic inflammation (statin type stratification).
Secondary objective
To identify the optimal dose for each statin to reduce 
systemic inflammation (statin dose stratification).
METHODS AND DESIGN
Population
The systematic review will include high- quality RCTs on 
adults of at least 18 years of age who have been treated 
with either atorvastatin, fluvastatin, pitavastatin, pravas-
tatin, rosuvastatin or simvastatin, and in whom LDL- C, and 
at least one of the following markers of systemic inflam-
mation: hsCRP, CRP, TNF-α, IL-1β, IL-6, IL-8, sCD14 or 
sCD16 are measured before and after statin treatment.
Patient and public involvement
This is a systemic review and meta- analysis protocol which 
will address the anti- inflammatory effects of statins. This 
study does not involve patients and/or the public at any 
stage as primary data will not be collected.
Study design
This systematic review will consider published and peer- 
reviewed randomised controlled clinical trials with at least 
one intervention arm of an FDA- licensed or European 
Medicines Agency (EMA)- licensed statin and a minimum 
treatment duration of 12 weeks.
Search strategy
The search strategy (see online supplementary file 1) 
aims to identify published and peer- reviewed articles with 
available full text. A stepwise approach will identify the 
selected articles. As indicated in figure 1, an initial limited 
search of Medline and Scopus will be undertaken; this will 
be followed by the analysis of the text words contained in 
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the titles and abstracts, and of the index terms used to 
describe each article. A second search, using all identi-
fied keywords and index terms, will then be undertaken 
across all included databases. In the third step, the refer-
ence lists of key articles will be searched for additional 
studies. Studies will be restricted to the English language 
and to those published from 1999 to 2019, inclusive. The 
databases that will be searched are Medline, Scopus, Web 
of Science and Cochrane Library of Systematic Reviews.
Eligibility criteria
Inclusion criteria
1. RCTs in humans.
2. Adults of at least 18 years of age.
3. At least one intervention arm including an FDA- 
licensed or EMA- licensed statin.
4. Minimum treatment duration of 12 weeks.
5. Studies that report the effects of statins on lipid profile 
LDL- C and inflammation markers hsCRP, CRP, TNF-α, 
IL-1β, IL-6, IL-8, sCD14 or sCD16.
6. Publication year: January 1999 to December 2019.
Exclusion criteria
1. RCT including participants with malignancies.
2. RCT including participants with autoimmune diseases.
3. RCT with cerivastatin (decommissioned from the mar-
ket) or lovastatin (not commonly prescribed anymore 
and its usage is associated with more risks than benefi-
cial effects) as intervention therapy.
4. Genetic studies.
Study selection
The primary selection of publications will depend on the 
information contained in their titles and abstracts and 
will be conducted by two independent investigators and 
reported using Preferred Reporting Items for Systematic 
Review and Meta- Analysis Protocols guidelines (see online 
supplementary file 2). When the reviewers disagree, the 
article will be re- assessed by a third reviewer.
Quality assessment
Two reviewers will independently verify selected articles 
to reduce the source of bias. All selected RCTs will be 
graded for their quality based on the Jadad Scale (see 
online supplementary file 3), the Oxford quality scoring 
system which is a widely used checklist for classification of 
quality of evidence.57
Risk of bias assessment
Two reviewers will assess the risk of bias, based on the 
Cochrane Risk of Bias Tool for RCTs (see online supple-
mentary file 4). The source of bias will be judged as 
high, low or unclear for the following domains: random 
sequence generation, blinding of participants and 
personnel, blinding of outcome assessment, incomplete 
outcome data, selective reporting of outcome and other 
sources of bias.
Data extraction
Quantitative and qualitative data will be extracted from 
selected papers: higher scores in grading, low risk in the 
evaluation and depending on publication bias tool used. 
The data extracted will include three domains: (1) identi-
fication of the study (year publication, first author’s name, 
PubMed identification number, title, journal name and 
impact factor); (2) methodology (study type, co- medica-
tion with statin intervention, target population (median/
mean age, gender distribution, race), target condition, 
comorbidities, statin, type, dose, duration) and (3) 
outcomes (change (or relevant data to estimate change) 
in lipid profile LDL- C and inflammation markers hsCRP, 
CRP, TNF-α, IL-1β, IL-6, IL-8, sCD14 or sCD16). For data 
extraction, two independent Microsoft Excel spread-
sheets will be compiled by two reviewers to summarise 
the data from the included studies. The spreadsheets 
will then be combined into one. The overall agreement 
rate between the two investigators will be calculated using 
Cohen’s κ statistic. Disagreements will be resolved by a 
third investigator.
Management of missing data
The investigator will be contacted via email in the case 
that key study specifics or outcome data are missing. If 
Figure 1 A schematic process of the systemic review. 
CRP,C reactive protein; hsCRP, high- sensitive C reactive 
protein;IL, interleukin; PRISMA- P, Preferred Reporting Items 
for Systematic Review and Meta- Analysis Protocol; RCT, 
randomised controlled clinical trial; TNF-α, tumour necrosis 
factor alpha.
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a response is not received within 2 weeks, a reminder 
email will be sent. A further 2 weeks waiting period will 
be allowed for responses; if no response or connection 
is established with the investigator, these studies will be 
excluded from the analysis.
Data management
Data management will be the responsibility of investiga-
tors. A Google Drive folder with shared access among the 
investigators will be provided for the systematic review 
which will encompass the protocol, manuscripts and 
supplementary files from included and excluded studies, 
as well as documentation of steps in data extraction and 
analysis, risk of bias and quality assessment. A back- up 
of the records will be stored on a second hard drive. 
EndNote V.X9 reference management software will be 
used in the study.
Outcomes
The primary outcome is the mean difference in systemic 
inflammatory markers and the secondary outcome is the 
change in lipid profile between study arms at the end 
of the statin intervention. The outcomes of the systemic 
review will be classified into primary and secondary 
outcomes as follows:
1. Systemic inflammatory markers: Data will be provid-
ed as a change in percent over time for hsCRP, CRP, 
TNF-α, IL-1β, IL-6, IL-8, sCD14 or sCD16.
2. Lipid profile: Data will be provided as a change in per-
cent over time for total cholesterol, LDL, high- density 
lipoprotein and triglycerides.
ANALYSIS
Descriptive analysis
Studies will be categorised by each type of statin inter-
vention and comparison, with data tabulated in narrative 
form to illustrate the study populations, interventions, 
durations and outcomes. The outcomes from included 
studies will provide the following:
1. Type of intervention (statin) and sample size.
2. Intervention outcomes will include the change in lip-
id profile and other inflammatory biomarkers such as 
hsCRP, CRP, TNF-α, IL-1β, IL-6, IL-8, sCD14 or sCD16.
The outcomes will be analysed together using the 
Cochrane Review Manager V.5.3 software, according to 
the guidelines outlined in the Cochrane Handbook for 
Systematic Reviews of Interventions. If statistical heter-
ogeneity is detected, the random- effects model will be 
adopted. In terms of considerable statistical heteroge-
neity, a qualitative summary will be provided by a table, 
as described above. This will be done by the lead inves-
tigator in liaison with a second investigator for accuracy.
Statistical analysis
We will analyse dichotomous data as risk ratios or ORs 
with 95% CIs and continuous data as mean differences 
or standardised mean differences. We will perform meta- 
analyses only if the treatment participants (age group), 
the underlying clinical question (disease type) and 
outcomes (assessed inflammatory markers) are similar 
enough. If an RCT consists of multiple arms, we will 
include only the relevant arms. A meta- analysis on LDL- C 
will be performed to assess the potency of statins; for each 
study, this will be reported as standardised mean differ-
ences with its 95% CI. A scatter plot of the percentage 
change in LDL- C against percentage change in inflam-
matory biomarkers over a specific time period will be 
performed to assess the correlation between lipid profile 
and inflammation. Heterogeneity and potential sources 
of heterogeneity will be assessed and quantified using 
I2 and Q statistics. Funnel plot and Egger’s test will be 
used to assess publication and small sample size bias. 
Subgroup analysis of identified studies will be stratified 
based on statin type, concentration and intervention 
period. Univariable and multivariable meta- regression 
analysis will be used to investigate the potential sources 
of heterogeneities. Potential outliers will be investigated 
in a sensitivity analysis by dropping each study at a time. 
The Duval and Tweedie trim- and- fill will be used to adjust 
estimates for the effects of publication bias, if any.
This systematic review will provide further insight into 
the effectiveness of statins to reduce systemic inflamma-
tion in various stages of chronic disease conditions, inform 
on the most potent statin to reduce systemic inflammation 
and optimal dosing. In addition, this study will add and 
improve the existing knowledge of the effects of statins 
on inflammatory markers and may further provide a basis 
for future clinical trials in specific diseases.
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